Sarah A Hudson

US Patent:

20060252818, Nov 9, 2006

Filed:

May 5, 2006

Appl. No.:

11/429018

Inventors:

Mehrak Kiankarimi - Carlsbad CA, US
Sarah Hudson - San Diego CA, US
Wesley Dwight - Poway CA, US
Warren Wade - San Diego CA, US

International Classification:

A61K 31/382
A61K 31/353
C07D 335/06

US Classification:

514432000, 514456000, 549023000, 549403000

Abstract:

Monoamine re-uptake inhibitors and more specifically serotonin and noradrenaline re-uptake inhibitors are disclosed that have utility in the treatment of disorders of the central or peripheral nervous system in both men and women. The compounds of this invention have the structure: wherein R, R, R, R, R, R, m, n, W, X, and Y are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts, esters and solvates thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting monoamine re-uptake in a subject in need thereof.

US Patent:

20120040985, Feb 16, 2012

Filed:

Feb 12, 2010

Appl. No.:

13/148811

Inventors:

Venkataiah Bollu - San Diego CA, US
Brant Clayton Boren - San Diego CA, US
Jackaline Dalgard Julien - Del Mar CA, US
Brenton T. Flatt - Poway CA, US
Nadia Haq - Waltham MA, US
Sarah Hudson - San Diego CA, US
Raju Mohan - Encinitas CA, US
Michael Morrissey - Danville CA, US
Benjamin Pratt - Encinitas CA, US
Richard Martin - San Diego CA, US
Xiao-Hui Gu - Potomac MD, US

Assignee:

EXELIXIS PATENT COMPANY LLC - SAN FRANCISCO CA

International Classification:

A61K 31/5377
A61K 31/498
A61K 31/473
A61K 31/423
A61K 31/4196
C07D 233/84
C07D 413/06
C07D 403/06
C07D 403/12
C07D 249/12
A61K 31/4164
C07D 405/14
A61P 3/00
A61P 3/04
A61P 9/10
A61P 3/10
A61P 3/06
C12N 5/02

US Classification:

5142362, 435375, 514249, 514314, 514379, 514381, 514383, 514398, 544132, 544353, 546167, 548241, 548252, 5482642, 5483251

Abstract:

The present invention comprises TGR5 agonists of structural formula I,wherein X, R, R, and Rare defined herein, as well as N-oxides of them and pharmaceutically acceptable salts thereof. The invention further comprises composition comprising the compounds, N-oxides, and/or pharmaceutically acceptable salts thereof. The invention also comprises use of the compounds and compositions for treating diseases in which TGR5 is a mediator or is implicated. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases in which TGR5 is a mediator or is implicated.

US Patent:

20130303505, Nov 14, 2013

Filed:

Aug 11, 2010

Appl. No.:

13/515132

Inventors:

Venkataiah Bollu - San Diego CA, US
Brant Clayton Boren - San Diego CA, US
Jackaline Dalgard Julien - Del Mar CA, US
Brenton T. Flatt - Poway CA, US
Nadia Haq - Waltham MA, US
Sarah Hudson - San Diego CA, US
Raju Mohan - Encinitas CA, US
Michael Morrissey - Danville CA, US
Benjamin Pratt - Encinitas CA, US

International Classification:

C07D 487/08
A61K 31/4995
A61K 31/496
A61K 31/454
A61K 31/4439
A61K 31/4196
A61K 31/4178
A61K 31/4164
C07D 295/15
C07D 401/12
C07D 249/12
C07D 403/12
C07D 233/84
C07D 233/64
A61K 31/5377

US Classification:

5142102, 5142358, 514248, 51425405, 514326, 514341, 514384, 514397, 514398, 514400, 544139, 544351, 544370, 546210, 5462744, 5482642, 5483137, 5483251, 5483435

Abstract:

TGR5 agonists of structural formula VIII(Q), wherein X, R, R, and Rare defined in the specification, pharmaceutically acceptable salts thereof, compositions thereof, and use of the compounds and compositions for treating diseases. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases.

US Patent:

20040259931, Dec 23, 2004

Filed:

Mar 8, 2004

Appl. No.:

10/797487

Inventors:

Val Goodfellow - Encinitas CA, US
Martin Rowbottom - San Diego CA, US
Brian Dyck - San Diego CA, US
Junko Tamiya - Oceanside CA, US
Mingzhu Zhang - San Diego CA, US
Jonathan Grey - San Diego CA, US
Troy Vickers - San Diego CA, US
Mehrak Kiankarimi - San Diego CA, US
Warren Wade - San Diego CA, US
Sarah Hudson - San Diego CA, US

Assignee:

Neurocrine Biosciences, Inc. - San Diego CA

International Classification:

A61K031/4025
C 07D 4 3/02

US Classification:

514/422000, 548/517000

Abstract:

Melanin-concentrating hormone (MCH) receptor antagonists are disclosed having utility for the treatment of MCH receptor-based disorders such as obesity. The compounds of this invention have the following structure: including stereoisomers and pharmaceutically acceptable salts thereof, wherein n, R, R, R, R, R, and Rare as defined herein. Pharmaceutical compositions containing a compound of this invention, as well as methods relating to the use thereof, are also disclosed.

US Patent:

20180362519, Dec 20, 2018

Filed:

Jan 27, 2017

Appl. No.:

16/072291

Inventors:

- New York NY, US
- Ringaskiddy, Co. Cork, IE
Longfei XIE - Groton CT, US
Carolyn LEVERETT - Groton CT, US
Beth C. VETELINO - North Stonington CT, US
Sai Chetan K. SUKURU - Glastonbury CT, US
Sarah HUDSON - San Diego CA, US
Venkata Ramana DOPPALAPUDI - San Diego CA, US
Abhijit S. BHAT - Winchester MA, US

Assignee:

PFIZER INC. - New York NY
CovX Technologies Ireland Limited - Ringaskiddy, Co. Cork

International Classification:

C07D 417/12
A61K 47/65
A61K 47/68
A61P 35/00
C07D 277/56

Abstract:

The present invention is directed to novel cytotoxic tubulysin analogs and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.